AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/553,273

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (canceled).

2. (withdrawn-currently amended): The agent method according to claim 4 31, which comprises a compound represented by the formula:

$$\begin{array}{c|c}
R^4 \\
\hline
C & L - N \\
R^5 \\
\hline
X & (II) \\
R^1 & O
\end{array}$$

wherein L represents a linker, R⁴ and R⁵ each represents a hydrogen atom, an optionally substituted hydrocarbon group, an acyl group, an optionally substituted carbamoyl group, an esterified carboxyl group, or an optionally substituted hydrerocyclic group, R⁴ and R⁵ may be taken together to form a ring, or a R⁴ or R⁵ may be taken together with a linker represented by L to form a ring, a ring C represents an optionally further substituted benzene ring, and the other symbols are as defined in claim ±31, or a salt thereof, or a prodrug thereof.

3. (withdrawn-currently amended): The agent method according to claim 4,31 which comprises a compound represented by the formula:

$$\begin{array}{c|c}
R^4 \\
\hline
C & L - N \\
R^5 \\
\hline
N & O
\end{array}$$
(III)

wherein a ring D represents an optionally substituted benzene ring, L represents a linker, R^4 and R^5 each represents a hydrogen atom, an optionally substituted hydrocarbon group, an acyl group, an optionally substituted carbamoyl group, an esterified carboxyl group, or an optionally substituted heterocyclic group, R^4 and R^5 may be taken together to form a ring, or R^4 or R^5 may be taken together with a linker represented by L to form a ring, a ring C represents an optionally further substituted benzene ring, and the other symbols are as defined in claim 4.31, or a salt thereof, or a prodrug thereof.

4. (withdrawn-currently amended): The agent method according to claim +31, which comprises a compound represented by the formula:

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/553,273

$$\begin{array}{c|c}
R^4 \\
\hline
C & L^{\frac{1}{N}} & R^5 \\
\hline
O & H & (IV) \\
\hline
R^1 & O & R^6
\end{array}$$

wherein a ring D represents an optionally substituted benzene ring, L¹ represents a linker represented by optionally substituted -Y-(CH₂)m- (Y represents a bond, -O-, -S(O)n¹- (n¹ represents an integer of 0 to 2) or -NR⁷- (R⁷ represents a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group), and m represents an integer of 0 to 6), R⁴ and R⁵ each represents a hydrogen atom, an optionally substituted hydrocarbon group, an acyl group, an optionally substituted carbamoyl group, an esterified carboxyl group or an optionally substituted heterocyclic group, R⁴ and R⁵ may be taken together to form a ring, or R⁴ or R⁵ may be taken together with a linker represented by L¹ to form a ring, a ring C represents an optionally further substituted benzene ring, R⁶ represents an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group, and the other symbols are as defined in claim 131, or a salt thereof, or a prodrug thereof.

5. (withdrawn-currently amended): The agent method according to claim 4_31₅ which is an analgesic, an agent for exhibiting analgesic activity, for promoting analgesic activity of another an analgesic drug, or an agent for avoiding resistance due to another an analgesic drug.

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q101065

Application No.: 10/553,273

6. (withdrawn-currently amended): The agent method according to claim 4_31, which is an agent for modulating modulates the prolactin secretion.

- 7. (withdrawn-currently amended): The agent method according to claim 4_31, which is an agent for preventing or treating hyperprolactinemia, pituitary gland tumor, diencephalons tumor, emmeniopathy, stress, autoimmune disease, prolactinoma, infertility, impotence, amenorrhea, galactic leakage, acromegaly, Chiari-Frommel syndrome, Argonz-del Castilo syndrome, Forbes-Albright syndrome, breast cancer lymphoma, Sheehan's syndrome or spermatogenesis abnormality.
- 8. (withdrawn-currently amended): The agent method according to claim 1, 31 which is an agent for suppressing the pancreatic glucagon secretion, an agent for lowering a blood glucose or an agent for suppressing the urine production.
- 9. (withdrawn-currently amended): The agent method according to claim 1, 31 which is an agent for preventing or treating diabetes, glucose tolerance disorder, ketosis, acidosis, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, pollakiuria, nocturnal enarusis, hyperlipemia, sexual function disorder, skin disease, arthritis, osteopenia, arteriosclerosis, thrombotic disease, maldigestion or memory and learning disabilities.
- 10. (withdrawn-currently amended): The agent method according to claim 1, 31 which is an agent for suppressing the bladder constriction.

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q101065

Application No.: 10/553,273

11. (withdrawn-currently amended): The agent method according to claim 1, 31 which is an agent for preventing or treating urine incontinence, lower uropathy, urge micturition due to excessive active bladder, or hypotonic bladder accompanied with excessive active bladder.

12. (withdrawn): A compound represented by the formula:

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
 & R^{5}
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
 & R^{5}
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
 & R^{5}
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
 & R^{5}
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
 & R^{5}
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
 & R^{5}
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
 & R^{5}
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
 & R^{5}
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
 & R^{5}
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
 & R^{5}
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
 & R^{5}
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
 & R^{5}
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
 & R^{5}
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
 & R^{5}
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
 & R^{5}
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
 & R^{5}
\end{array}$$

wherein a ring D represents an optionally substituted benzene ring, G¹ represents a bond, or an optionally substituted divalent hydrocarbon group, G² represents -O-, -NR⁸- (R⁸ represents a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group) or -S(O)n²- (n² represents an integer of 0 to 2), G³ represents an optionally substituted divalent hydrocarbon group, R⁴ and R⁵ each represents a hydrogen atom, an optionally substituted hydrocarbon group, an acyl group, an optionally substituted carbamoly group, an esterified carboxyl group, or an optionally substituted heterocyclic group, a ring C represents an optionally further substituted benzene ring, R¹ and R² each represents a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/553,273

formula:

group, R⁴ may be taken together with G³ or R⁵ to form a ring and, when G² is -NR⁸-, R⁴ and R⁸ may be taken together to form a ring, provided that 3,5-trans-N-(2-fluorobenzyl)-5-[3-(3-tertbutoxycarbonylaminopropyl)aminomethylphenyl]-7-chloro-1-neopentyl-2-oxo-1,2,3,5tetrahydro-4,1-benzooxazepine-3-acetamide, 3,5-trans-N-(2-fluorobenzyl)-5-[3-(3aminopropyl)aminomethylphenyl]-7-chloro-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1benzooxazepine-3-acetamide, 3,5-trans-N-(2-fluorobenzyl)-5-(3aminoacetylaminomethylphenyl)-1-benzyl-7-chloro-2-oxo-1,2,3,5-tetrahydro-4,1benzooxazepine-3-acetamide, 3,5-trans-N-(2-fluorobenzyl)-1-(4-biphenylmethyl)-7-chloro-2oxo-5-[3-[(piperidin-4-yl)carbonylaminomethyl]phenyl]-1,2,3,5-tetrahydro-4,1-benzooxazepine-3-acetamide, 3,5-trans-N-(2-fluorobenzyl)-5-[2-(3-aminopropyloxy)phenyl]-7-chloro-1-isobutyl-2-oxo-1,2,3,5-tetrahydro-4,1-benzooxazepine-3-acetamide, 3,5-trans-N-(2-fluorobenzyl)-5-[4-(3aminopropyloxy)-2-methoxyphenyl]-7-chloro-1-neopentyl-2-oxo-1,2,3,5-tetrahydro-4,1benzooxazepine-3-acetamide, 7-chloro-5-[2-[3-[[(1,1dimethylethoxy)carbonyl]amino]propoxy]phenyl]-1,2,3,5-tetrahydro-1-(2-methylpropyl)-2-oxo-4,1-benzooxazepin-3-ylacetic acid ethyl ester, and 7-chloro-5-[4-[3-[[(1,1dimethylethoxy)carbonyl]amino]propoxy]-2-methoxyphenyl]-1-(2,2-dimethylpropyl)]-1,2,3,5tetrahydro-2-oxo-4.1-benzooxazepin-3-ylacetic acid ethyl ester are excluded, or a salt thereof.

13. (withdrawn): The compound according to claim 12, which is represented by the

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/553,273

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
O & & \\
R^{5}
\end{array}$$

$$\begin{array}{c|c}
R^{4} \\
R^{5}
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
O & & \\
R^{1}
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
O & & \\
O & & \\
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
O & & \\
O & & \\
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
O & & \\
O & & \\
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
O & & \\
O & & \\
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
O & & \\
O & & \\
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
O & & \\
O & & \\
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
O & & \\
O & & \\
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
O & & \\
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
O & & \\
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
O & & \\
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
O & & \\
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
O & & \\
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{3} - N \\
\hline
\end{array}$$

$$\begin{array}{c|c}
C & G^{1} - G^{2} - G^{2} - N \\
\hline
\end{array}$$

$$\begin{array}{c$$

wherein J represents an optionally substituted hydroxy group, or an optionally substituted amino group, and the other symbols are as defined in claim 12.

14. (withdrawn): The compound according to claim 12, which is represented by the formula:

$$\begin{array}{c|c}
C & G^{\frac{1}{2}} & G^{\frac{2}{3}} & N \\
\hline
C & G^{\frac{1}{2}} & G^{\frac{2}{3}} & N \\
\hline
O & & & & \\
R^{5} & & & \\
\hline
O & & & & \\
R^{6} & & & & \\
R^{1} & & & & \\
\end{array}$$
(IV')

wherein R⁶ represents an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group, and the other symbols are ad defined in claim 12.

15. (withdrawn): The compound according to claim 12, wherein G^1 is a bond, or an optionally substituted C_{1-3} alkylene group.

AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q101065

Application No.: 10/553,273

16. (withdrawn): The compound according to claim 12, wherein G^3 is an optionally substituted C_{2-6} alkylene group.

- 17. (withdrawn): The compound according to claim 12, wherein G^1 is a bond, and G^2 is -O-.
- **18.** (withdrawn): The compound according to claim 12, wherein R¹ is an optionally substituted hydrocarbon group.
- 19. (withdrawn): The compound according to claim 12, wherein R^1 is an optionally substituted C_{1-8} alkyl group, or an optionally substituted C_{7-16} aralkyl group.
- **20.** (withdrawn): The compound according to claim 12, wherein R⁴ is a hydrogen atom.
- 21. (withdrawn): The compound according to claim 12, wherein R^5 is an optionally substituted C_{1-6} alkyl group, or an optionally substituted C_{7-16} aralkyl group.
- **22.** (withdrawn): The compound according to claim 13, wherein J is a hydroxy group, an optionally substituted lower alkoxy group, an amino group optionally substituted with an optionally substituted alkyl group, or an optionally substituted cyclic amino group.

Application No.: 10/553,273

23. (withdrawn): The compound according to claim 13, wherein J is an optionally substituted 5- to 8- membered cyclic amino group.

24. (withdrawn): The compound according to claim 14, wherein R⁶ is an optionally substituted benzyl group, or an optionally substituted phenyl group.

25. (withdrawn): The compound according to claim 12, wherein G^3 is an optionally substituted divalent hydrocarbon group other than a carbonyl group and, when R^4 is a hydrogen atom, R^5 is not a hydrogen atom or a tert-butyloxycarbonyl group.

26. (withdrawn): A compound represented by the formula:

$$\begin{array}{c|c}
C & & R^4 \\
\hline
C & & R^5 \\
\hline
O & & R^2 \\
\hline
R^1 & & O
\end{array}$$
(III'''')

wherein a ring D represents an optionally substituted benzene ring, G^3 represents an optionally substituted divalent hydrocarbon group, R^4 and R^5 each represents a hydrogen atom, an optionally substituted hydrocarbon group, an acyl group, an optionally substituted carbamoyl group, an esterified carboxyl group, or an optionally substituted heterocyclic group, a ring C represents an optionally further substituted benzene ring, R^1 and R^2 each represents an hydrogen

AMENDMENT UNDER 37 C.F.R. § 1.111

Application No.: 10/553,273

atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group, and R⁴ may be taken together with G³ or R⁵ to form a ring,

or a salt thereof.

27. (withdrawn): 2-(3,5-trans-7-Chloro-1-(2,2-dimethylpropyl)-5-{2-methoxy-3-[3-(3phenylpropylamino)propoxylphenyl}-2-oxo-1,2,3,5-tetrahydro-4,1-benzooxazepin-3-yl)-N-(2 $fluorobenzyl) acetamide, 2-\{3,5-trans-7-chloro-1-(2,2-dimethylpropyl)-5-\lceil 2-methoxy-3-(3-methylpropyl)-5-\lceil 2-methylpropyl)-5-\lceil 2-methoxy-3-(3-methylpropyl)-5-\lceil 2-methylpropyl)-5-\lceil 2-methylpropyl-3-(3-methylpropyl)-5-\lceil 2-methylpropyl-3-(3-methylpropyl-3-methylpropyl-3-(3-methylpropyl-3-methylpropyl-3-(3-methylpropyl-3-methylpropyl-3-(3-methylpropyl-3-methylpropyl-3-methylpropyl-3-(3-methylpropyl-3-methylpropyl-3-(3-methylpropyl-3-methylpropyl-3-methylpropyl-3-(3-methylpropyl-3-methylpropyl-3-(3-methylpropyl-3-methylpropyl-3-(3-methylpropyl-3-methylpropyl-3-(3-methylpropyl-3-methylpropyl-3-(3-methylpropyl-3-methylpropyl-3-(3-methylpropyl-3-methylpropyl-3-(3-methylpropyl-3-methylpropyl-3-(3-methylpropyl-3-methylpropyl-3-(3-methylpropyl-3-methylpropyl-3-(3-methylpropyl-3-$ (pentylamino)propoxy)phenyl]-2-oxo-1,2,3,5-tetrahydro-4,1-benzooxazepin-3-yl}-N-(2-2-methoxyphenyl]-1-(2,2-dimethylpropyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzooxazepin-3-yl}-N-(2-fluorobenzyl)acetamide, trans-2-[7-chloro-1-(2,2-dimethylpropyl)-5-[2-methoxy-3-(3-{[(2E)-3-phenyl-2-propenyl]amino}propoxy)phenyl]-2-oxo-1,2,3,5-tetrahydro-4,1-benzooxazepin-3yl]-N-(2-fluorobenzyl)acetamide, trans-2-[7-chloro-1-(2,2-dimethylpropyl)-5-(2-methoxy-3-{3-[(3-phenylpropyl)amino]propoxy}phenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzooxazepin-3-yl]-Npropylacetamide, trans-7-chloro-1-(2,2-dimethylpropyl)-5-(2-methoxy-3-{3-[(3phenylpropyl)amino]propoxy}phenyl)-3-[2-oxo-2-(1-piperazinyl)ethyl]-1,5-dihydro-4,1benzooxazepine-2(3H)-one, trans-7-chloro-1-(2,2-dimethylpropyl)-3-[2-(4-hydroxypiperidin-1yl)-2-oxoethyl]-5-(2-methoxy-3-{3-[(3-phenylpropyl)amino]propoxy}phenyl)-1,5-dihydro-4,1benzooxazepine-2(3H)-one or 4-{[3,5-trans-7-chloro-1-(2,2-dimethylpropyl)-5-(2-methoxy-3-{3-[(3-phenylpropyl)amino|propoxy}phenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzooxazepin-3yl]acetyl}piperazine-2-carboxylic acid, or a salt thereof.

28. (canceled).

Application No.: 10/553,273

29. (withdrawn-currently amended): A drug comprising the compound according to claim 12 or 26 or a prodrug thereof.

30. (withdrawn-currently amended): The drug according to claim 29, which is an agent a pharmaceutical composition for preventing or treating RFRP-associated with morbid state or a disease involved in RFRP.

31. (**original**): A method of modulating the function of an RFRP receptor, which comprises administering an effective amount of a compound represented by the formula:

$$\begin{array}{c|c}
\hline
 & B \\
\hline
 & X \\
\hline
 & R^2 \\
\hline
 & R^1 \\
\hline
 & O
\end{array}$$

wherein a ring A represents an optionally substituted aromatic ring, a ring B represents an optionally substituted benzene ring, X represents O, S(O)n (n represents an integer of 0 to 2) or NR³ (R³ represents a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic group), and R¹ and R² each represents a hydrogen atom, an optionally substituted hydrocarbon group, or an optionally substituted heterocyclic ring, or a salt thereof, or a prodrug thereof to a mammal.

32. (canceled).